Vascular endothelial growth factor and insulin-like growth factor-1 in preterm infants with retinopathy of prematurity

Ali Peirovifar1, MD, Manizheh Mostafa Gharehbaghi2, MD, Parvin Mostafa Gharabaghi3, MD, Karim Sadeghi4, MD

1Department of Anesthesiology, 2Women’s Reproductive Health Research Center, Department of Pediatrics and Neonatology, 3Women’s Reproductive Health Research Center, Department of Obstetrics and Gynecology, 4Department of Ophthalmology, Tabriz University of Medical Sciences, Tabriz, Iran

Correspondence: Dr Manizheh Mostafa Gharehbaghi, Professor, Neonatal Intensive Care Unit, Al Zahra Hospital, South Arthesh Street, 513864449, Tabriz, Iran. gharehbaghimm@yahoo.com

INTRODUCTION Retinopathy of prematurity (ROP) can lead to severe visual impairment. This study was conducted to determine the levels of biochemical mediators (i.e. vascular endothelial growth factor [VEGF] and insulin-like growth factor-1 [IGF-1]) in the blood of premature infants with proliferative ROP.

METHODS Blood samples from 71 preterm infants born at or before 32 weeks of gestation were obtained 6–8 weeks after birth. These infants were classified into two groups according to their eye examination results. The control group consisted of 41 infants who had no evidence of ROP, and the study group consisted of 30 infants with proliferative ROP at stage III or higher. Blood VEGF and IGF-1 levels were measured using enzyme-linked immunosorbent assay.

RESULTS The mean gestational ages of the infants at birth were 28.4 ± 1.6 and 28.8 ± 1.6 weeks in the study and control groups, respectively (p = 0.259). The mean postmenstrual age of the infants at the time of blood sampling was 34.9 ± 1.2 weeks in the study group and 34.6 ± 1.3 weeks in the control group (p = 0.339). The mean blood IGF-1 (18.48 ± 11.79 µg/L and 16.75 ± 13.74 µg/L in the study and control groups, respectively; p = 0.580) and VEGF (267.35 ± 103.43 pg/mL and 237.52 ± 130.92 pg/mL in the study and control groups, respectively; p = 0.305) levels of the infants were not significantly different between the two groups.

CONCLUSION At 6–8 weeks after birth, blood IGF-1 and VEGF levels were not found to be significantly different between premature infants with proliferative ROP and those without.

Keywords: insulin-like growth factor, retinopathy of prematurity, vascular endothelial growth factor
week after birth. The ophthalmologist recommended follow-up eye examinations where necessary, based on the retinal findings, which were classified according to international standards of classification. All preterm infants with ROP stage III or higher at the follow-up eye examination were assigned to the study group (n = 30), while preterm infants with normal eye examination results at 6–8 weeks after birth were included in the control group (n = 41). The ethics committee of the university approved the study. Written informed parental consent was also obtained in all cases.

Blood samples were collected at the time of follow-up eye examination, which was at 6–8 weeks after birth. The samples were centrifuged at 3,000 rpm and stored at −70°C. Laboratory analysis was blinded to the infant groups. IGF-1 and VEGF levels were measured by quantitative sandwich enzyme-linked immunosorbent assay (ELISA) using IDS IGF-1 (AC27F1; Immunodiagnostic Systems Ltd, Boldon, UK) and IBL ELISA kits (27171; Medical & Biological Laboratories Co Ltd, Nagoya, Japan) for IGF-1 and VEGF measurement, with sensitivity of 3.1 µg/L and 1.01 pg/mL, respectively. Statistical analysis was performed using the Statistical Package for the Social Sciences version 15 (SPSS Inc, Chicago, IL, USA). Categorical variables were evaluated using chi-square and Fisher’s exact tests. Continuous variables were compared using either t-test (for normally distributed data) or Mann-Whitney U-test (for data with a skewed distribution). A p-value of < 0.050 was considered statistically significant.

RESULTS
We included 71 preterm newborn infants in this study, out of which 30 were diagnosed with proliferative ROP (i.e. the study group) and 41 had normal ophthalmologic examinations (i.e. the control group). The demographic characteristics of the infants in the two groups are shown in Table I.

The study group’s Apgar scores at 1 and 5 mins after birth were significantly lower than those in the control group (p < 0.001 and p = 0.001, respectively). Surfactant replacement therapy was done for 11 (26.8%) infants in the control group and 15 (50%) infants in the study group (p = 0.045). The two groups were significantly different with regard to the need for surfactant replacement therapy, duration of mechanical ventilation, and respiratory support requirements (Table II). Blood transfusion was done in 17 (56.7%) and 19 (46.3%) infants in the study and control groups, respectively (p = 0.390). Sepsis was diagnosed in 5 (16.7%) and 2 (4.9%) infants in the study and control groups, respectively (p = 0.125).

The mean blood levels of IGF-1 in the study and control groups were 18.48 ± 11.79 (95% confidence interval [CI] 14.1–22.9) µg/L and 16.75 ± 13.74 (95% CI 12.4–21.1) µg/L, respectively (p = 0.580). The mean blood levels of VEGF in the study and control groups were 267.35 ± 103.43 (95% CI 228.9–511.5) pg/mL and 237.52 ± 130.92 (95% CI 196.2–278.8) pg/mL, respectively (p = 0.305). The mean levels of the studied biochemical markers in the preterm infants are shown in Table III.

Diode laser photocoagulation was performed in 21 infants with threshold ROP. Mean IGF-1 levels in infants of different postmenstrual ages is showed in Table IV.

DISCUSSION
ROP is an important cause of blindness in both developed and developing countries. World Health Organization’s
VISION 2020 programme delineates ROP as a preventable disease that requires early detection and treatment to prevent blindness and reduce inherent costs to the individual and community. It has been long believed that oxygen therapy leads to an increased risk of ROP in preterm infants. However, ROP can occur even with careful use of oxygen. Several factors increase the risk of ROP, including low gestational age, low birth weight, sepsis, intraventricular haemorrhage, blood transfusion and mechanical ventilation. In our study, we found lower Apgar scores and severe respiratory distress (which manifested as a need for surfactant replacement therapy), longer assisted ventilation and use of continuous positive airway pressure to be significantly more common in infants who developed proliferative ROP. Our findings concur with the findings in a study by Karna et al.

With respect to the pathogenesis of ROP, inhibition of vascularisation in the early phase of ROP has been attributed to the hypoxic suppression of VEGF. A lack of IGF-1 in this phase of ROP may also prevent normal retinal vascular growth. In phase II of ROP, pathologic vascular proliferation appears to be associated with rising levels of VEGF and IGF-1 induced by hypoxia. Several studies have also assessed IGF-1 and VEGF so as to define their role in the pathogenesis of ROP. Different studies have yielded different results – this may be due to variations in study design, the wide range of gestational ages and postnatal ages of study groups, different sample sizes and different stages of ROP. A study by Pérez-Muñuzuri et al. showed reduced IGF-1 levels in infants who developed ROP (n = 3) three weeks postpartum, independent of gestational age at birth; a rapid rise in IGF-1 levels between the third and fifth weeks postpartum appeared to be related to progression to a higher stage of ROP. Only three patients with proliferative ROP were included in Pérez-Muñuzuri et al’s study.

In another study, elevated VEGF and reduced IGF-1 levels were reported in infants with ROP, though the severity of ROP was specified. Hellström et al. conducted a study measuring serum IGF-1 levels weekly and showed that low serum IGF-1 levels correlated with a later development of ROP. Hellström et al also concluded that the mean IGF-1 level at postmenstrual weeks 30 to 33 is a predictive factor of ROP that is as important as the degree of prematurity. In our study, there was no statistically significant difference in IGF-1 and VEGF levels between preterm infants with proliferative ROP and those without at 6–8 weeks after birth. This lack of significant difference in VEGF and IGF-1 levels in the present study could be due to the higher postnatal and postmenstrual ages of our cohort at sampling. IGF-1 level is known to be affected by gestational age, birth weight, protein intake and stage of retinopathy. In our study, most of the infants in the study group were in the proliferative phase of ROP at sampling. In the more severe stages of ROP (at 6–8 weeks after birth), the blood levels of IGF-1 and VEGF reach levels not different from those in infants without ROP.

Our study has some limitations, such as the small cohort of infants. As there was a lack of serial measurement of biochemical markers, we could not show the variations in these parameters over time. However, an advantage of our study is that ophthalmologic examinations were performed consistently and all infants were seen by the same ophthalmologist for the entire duration of the study.

In conclusion, our data demonstrated that at 6–8 weeks after birth, the blood levels of IGF-1 and VEGF were not significantly different between premature infants with proliferative ROP and those without.

**REFERENCES**


### Table III. Level of biochemical markers in the preterm infants in the two groups.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Study group (n = 30)</th>
<th>Control group (n = 41)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean ± SD</td>
<td>95% CI</td>
<td></td>
</tr>
<tr>
<td>IGF-1 (μg/L)</td>
<td>18.48 ± 11.79</td>
<td>14.1–22.9</td>
<td></td>
</tr>
<tr>
<td>VEGF (pg/mL)</td>
<td>267.35 ± 103.43</td>
<td>228.9–511.5</td>
<td></td>
</tr>
</tbody>
</table>

CI: confidence interval; IGF-1: insulin-like growth factor-1; SD: standard deviation; VEGF: vascular endothelial growth factor

### Table IV. IGF-1 levels of the preterm infants according to different postmenstrual ages.

<table>
<thead>
<tr>
<th>Postmenstrual age (wks)</th>
<th>Study group (n = 30)</th>
<th>Control group (n = 41)</th>
<th>Total no. (n = 71)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean ± SD</td>
<td>95% CI</td>
<td>Mean ± SD</td>
</tr>
<tr>
<td>IGF-1* (μg/L)</td>
<td>No. of patients</td>
<td>IGF-1* (μg/L)</td>
<td>No. of patients</td>
</tr>
<tr>
<td>33</td>
<td>19.52 ± 13.43</td>
<td>4</td>
<td>13.4 ± 6.69</td>
</tr>
<tr>
<td>34</td>
<td>16.76 ± 12.74</td>
<td>6</td>
<td>19.94 ± 14.31</td>
</tr>
<tr>
<td>35</td>
<td>20.87 ± 13.68</td>
<td>12</td>
<td>20.18 ± 17.10</td>
</tr>
<tr>
<td>36</td>
<td>16.54 ± 9.34</td>
<td>5</td>
<td>7.7 ± 5.22</td>
</tr>
<tr>
<td>37</td>
<td>14.16 ± 7.21</td>
<td>3</td>
<td>5.4 ± 1</td>
</tr>
<tr>
<td>38</td>
<td>–</td>
<td>2</td>
<td>7.7 ± 10.88</td>
</tr>
</tbody>
</table>

*Data is presented as mean ± standard deviation. IGF-1: insulin-like growth factor-1


